Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients - Longterm follow-up

European Journal of Surgical Oncology

Volumn 34, Issue 1, 2008, Pages 6-12

  Fjosne H E ^a   Jacobsen, A B ^b   Lundgren, S ^a,c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Adjuvant endocrine treatment; Breast cancer; Cyclic treatment; Megestrol acetate; Randomized study; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; MEGESTROL ACETATE; METHOTREXATE; TAMOXIFEN CITRATE; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COURSE EVALUATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; EVALUATION; FEMALE; FLUID RETENTION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VAGINA BLEEDING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS;

EID: 37349054175     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.07.002     Document Type: Article

References (40)

1. Brennan M.J. Endocrinology in cancer of the breast. Status and prospects. Am J Clin Pathol 64 (1975) 797-809
2. Bonadonna G., Brusamolino E., Valagussa P., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294 (1976) 405-410
3. Fisher B., Slack N., Katrych D., and Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140 (1975) 528-534
4. Anon. Review of mortality results in randomised trials in early breast cancer. Lancet 2 (1984) 1205
5. Nolvadex Adjuvant Trial Organisation. Controlled trial of Tamoxifen as single adjuvant agent in management of early breast cancer: analysis at six years by Nolvadex Adjuvant Trial Organization. Lancet 1 (1985) 836-839
6. Report form the Breast Cancer trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh: adjuvant Tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet 330 (1987) 171-175
7. Mouridsen H.T., and Palshof T. Adjuvant systemic therapy in breast cancer: a review. Eur J Cancer Clin Oncol 19 (1983) 1753-1770
8. Fisher B., Redmond C., Brown A., et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305 (1981) 1-6
9. Gundersen S., Hannisdal E., Søreide J.A., Skarstein A., and Varhaug J.E. Adjuvant Tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study. Breast Cancer Res Treat 36 (1995) 49-53
10. Gazet J.C., Rainsbury R.M., Ford H.T., Powles T.J., and Coombes R.C. Survey of treatment of primary breast cancer in Great Britain. Br Med J 290 (1985) 1793-1795
11. Jensen E.V., and DeSombre E.R. Mechanism of action of the female sex hormones. Annu Rev Biochem 41 (1972) 203-230 [review]
12. Namer M., Lalanne C., and Baulieu E.E. Increase of progesterone receptor by Tamoxifen as a hormonal challenge test in breast cancer. Cancer Res 40 (1980) 1750-1752
13. Waseda N., Kato Y., Imura H., and Kurata M. Effects of Tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res 41 (1981) 1984-1988
14. Howell A., Harland R.N., Barnes D.M., et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of Tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47 (1987) 300-304
15. Lundgren S., Kvinnsland S., Varhaug J.E., and Utaaker E. The influence of progestins on receptor levels in breast cancer metastasis. Anticancer Res 7 (1987) 119-123
16. Gundersen S., Kvinnsland S., Lundgren S., et al. Cyclical use of Tamoxifen and high dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 17 (1990) 45-50
17. Lundgren S., Gundersen S., Klepp R., Lønning P.E., Lund E., and Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 14 (1989) 201-206
18. Lundgren S., Kvinnsland S., and Utaaker E. Oral high dose progestins as treatment for advanced breast cancer. Acta Oncol 28 (1989) 811-816
19. Morgan L.R. Megestrol acetate v Tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 12 (1985) 43-47
20. Thoresen T. Occupied and unoccupied nuclear oestradiol receptor in human breast tumours: relation to oestradiol and progesterone cytosol receptor. J Steriod Biochem 10 (1979) 661-668
21. Pocock S.J. Clinical trials. A practical approach (1983), Wiley & Sons Ltd, New York
22. Punglia R.S., Kuntz K.M., Winer E.P., Weeks J.C., and Burstein H.J. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 23 (2005) 5178-5187
23. Strasser-Weippl K., and Goss P.E. Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 23 (2005) 1751-1759 [review]
24. Belfiglio M., Valentini M., Pellegrini F., et al., Interdisciplinary Group for Cancer Care Evaluated (GIVIO) Group. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant Tamoxifen for postmenopausal early-stage breast carcinoma patients (SITam 01). Cancer 104 (2005) 2334-2339
25. Fernö M., Stål O., Baldetorp B., et al. Results of two or five years of adjuvant Tamoxifen correlated to steroid receptor and S-phase levels. Breast Cancer Res Treat 59 (2000) 69-76 South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group
26. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of Tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88 (1996) 1529-1542
27. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J., and Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
28. McGuire W.L., Horwitz K.B., Pearson O.H., and Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer 39 6 Suppl. (1977) 2934-2947 [review]
29. Hawkins R.A., White G., Bundred N.J., et al. Prognostic significance of oestrogen and progestogen receptor activities in breast cancer. Br J Surg 74 (1987) 1009-1013
30. Dowsett M., Houghton J., Iden C., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17 (2006) 818-826
31. De Lena M., Tommasi S., Schittulli F., Lorusso V., and Paradiso A. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study. Tumori 76 (1990) 190-195
32. Beltran M., Alonso M.C., Ojeda M.B., et al. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients. Ann Oncol 2 (1991) 495-499
33. Lundgren S., Søreide J.A., and Lea O. Influence of Tamoxifen on steroid receptor levels in primary breast cancer patients. Anticancer Res 14 (1994) 1313-1317
34. Makris A., Powles T.J., Allred D.C., et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 48 (1998) 11-20
35. Johnson P.A., Bonomi P.D., Anderson K.M., et al. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat Rep 67 (1983) 717-720
36. Tseng L., and Gurpide E. Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinol Metab 41 (1975) 402-404
37. Crawford D.J., George W.D., Smith D.C., Stewart M., Paul J., and Leake R.E. Cyclic sequential endocrine therapy for advanced breast cancer using a combination of Tamoxifen and megestrol acetate. Oncology 51 Suppl. 1 (1994) 13-18
38. Reid A.D., Horobin J.M., Newman E.L., and Preece P.E. Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast Cancer Res Treat 22 (1992) 153-156
39. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
40. Lundgren S., Jørgensen S., and Kåresen R. Surgery for breast cancer patients in Norway 1990-95. Tidskr Nor Lægeforen 121 (2001) 2688-2693 [in Norwegian]